一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> JAMA Network Open >>article
JAMA Network Open

JAMA Network Open

IF: 10.5
Download PDF

Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure

Published:2 May 2024 DOI: 10.1001/jamanetworkopen.2024.9305
Katherine L. Modzelewski, Alexandra Pipilas, Nicholas A. Bosch

Abstract

ImportanceSodium-glucose cotransporter-2 (SGLT2) inhibitors have been shown to have benefits when used in patients with heart failure. The comparative outcomes of SGLT2 inhibitors relative to each other has not been well defined and may impact medication selection.ObjectiveTo determine the comparative outcomes of empagliflozin and dapagliflozin on reducing the composite of all-cause mortality and hospitalizations in patients with heart failure.Design, Setting, and ParticipantsThis multicenter retrospective cohort study included patients with heart failure from August 18, 2021, and December 6, 2022, in the TriNetX Research Collaborative, a centralized database of deidentified electronic medical record data from a network of 81 health care organizations. Eligible patients had a diagnosis of heart failure, had never received an SGLT2 inhibitor previously, and were newly started on empagliflozin or dapagliflozin. Patients were followed up for 1 year.ExposureInitiation of dapagliflozin or empagliflozin.Main Outcomes and MeasuresThe primary outcome was the time to the composite of all-cause mortality or hospitalization between study days 1 to 365. Kaplan-Meier analyses, hazard ratios (HRs), and 95% CIs were used to assess the primary outcome.ResultsAmong 744 914 eligible patients, 28 075 began empagliflozin (15 976 [56.9%]) or dapagliflozin (12 099 [43.1%]). After nearest-neighbor matching for demographics, diagnoses, and medication use, there were 11 077 patients in each group. Of patients who received empagliflozin, 9247 (57.9%) were male, 3130 (19.6%) were Black individuals, and 9576 (59.9%) were White individuals. Similarly, of those who received dapagliflozin, 7439 (61.5%) were male, 2445 (20.2%) were Black individuals, and 7131 (58.9%) were White individuals. Patients receiving empagliflozin were less likely to experience the composite of all-cause mortality or hospitalization compared with those initiated on dapagliflozin (3545 [32.2%] vs 3828 [34.8%] events; HR, 0.90 [95% CI, 0.86-0.94]) in the year following SGLT2 inhibitor initiation and less likely to be hospitalized (HR, 0.90 [95% CI, 0.86-0.94]). All-cause mortality did not differ between exposure groups (HR, 0.91 [95% CI, 0.82-1.00]). There was no difference in mean hemoglobin A1c or adverse events between groups.Conclusions and RelevanceIn this cohort study, patients who initiated empagliflozin were less likely to experience the composite of all-cause mortality or hospitalization compared with patients who started dapagliflozin. Additional studies are needed to confirm these finding.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Dapagliflozin 461432-26-8 C21H25ClO6 828 suppliers $5.00-$1611.00
Empagliflozin 864070-44-0 C23H27ClO7 764 suppliers $5.00-$1950.00

Similar articles

增城市| 松江区| 利川市| 南郑县| 伊川县| 准格尔旗| 中卫市| 武义县| 雅江县| 商洛市| 溆浦县| 邢台县| 大港区| 民权县| 桂阳县| 蓬安县| 巫山县| 远安县| 济阳县| 盘山县| 司法| 平潭县| 宁德市| 永泰县| 诸暨市| 铜川市| 廉江市| 东丰县| 田林县| 彩票| 新田县| 莱阳市| 阿图什市| 罗甸县| 丹东市| 乐平市| 渝中区| 万荣县| 含山县| 获嘉县| 卫辉市|